PD1 may be effective in treating non-Hodgkin’s lymphoma, but the exact efficacy varies from person to person.
PD1 usually refers to PD1 monoclonal antibody, or treprostinil injection, which is a malignant tumor immunotherapy drug. There are PD-1 receptors on T-lymphocytes in the human body, and PD1 monoclonal antibody can block PD-1 on T-lymphocytes from binding to PD-L1 on the surface of tumor cells.
This can reduce or lift the immunosuppressive effect of tumor cells on immune cells (e.g., T lymphocytes), thus enabling the immune cells in the body to give full play to their anti-tumor cellular immunity to achieve the purpose of killing tumor cells.
Therefore, PD1 monoclonal antibody can be used for the treatment of non-Hodgkin’s lymphoma (e.g. peripheral T-cell lymphoma), and can play a certain therapeutic effect. However, the specific conditions of patients with non-Hodgkin’s lymphoma are different, and some patients are treated with PD1 monotherapy with remarkable efficacy, while others are not so effective.
It is recommended that patients with non-Hodgkin’s lymphoma consult a hematologist in time to have a treatment plan formulated by a specialist according to their specific condition and to assess whether PD1 monotherapy is appropriate.